British drugmaker GlaxoSmithKline Plc is collaborating with the Coalition for Epidemic Preparedness Innovations (CEPI) to contribute towards the effort of developing a vaccine for the coronavirus outbreak, GSK and CEPI said on Monday.
GSK will make its “adjuvant platform technology” available for developing a vaccine against the 2019-nCoV virus, according to the statement.
Read entire article here.
The Coalition for Epidemic Preparedness Innovations (CEPI) has announced the initiation of three programmes to develop vaccines against coronavirus.
The programmes will leverage rapid response platforms already supported by CEPI as well as a new partnership.
“The aim is to advance nCoV-2019 vaccine candidates into clinical testing as quickly as possible,” CEPI said in a statement.
CEPI was founded in Davos by the governments of Norway and India, the Bill & Melinda Gates Foundation, the Wellcome Trust, and the World Economic Forum.
Read entire article HERE.